Detalles de la búsqueda
1.
Discovery of a cyclopentylamine as an orally active dual NK1 receptor antagonist-serotonin reuptake transporter inhibitor.
Bioorg Med Chem Lett
; 24(6): 1611-4, 2014 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24507922
2.
Design, optimization, and in vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depression.
Bioorg Med Chem Lett
; 23(2): 407-11, 2013 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23253443
3.
Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression.
Bioorg Med Chem
; 21(8): 2217-2228, 2013 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23477943
4.
Comparison of zolpidem and midazolam self-administration under progressive-ratio schedules: consumer demand and labor supply analyses.
Exp Clin Psychopharmacol
; 15(4): 328-37, 2007 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-17696679
5.
Anti-conflict effects of benzodiazepines in rhesus monkeys: relationship with therapeutic doses in humans and role of GABAA receptors.
Psychopharmacology (Berl)
; 184(2): 201-11, 2006 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-16378217
6.
Effects of CRF1 receptor antagonists and benzodiazepines in the Morris water maze and delayed non-matching to position tests.
Psychopharmacology (Berl)
; 178(4): 410-9, 2005 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15765256
7.
Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists.
J Med Chem
; 47(23): 5783-90, 2004 Nov 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-15509177
8.
The anxiolytic CRF(1) antagonist DMP696 fails to function as a discriminative stimulus and does not substitute for chlordiazepoxide in rats.
Psychopharmacology (Berl)
; 166(4): 408-15, 2003 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-12590355
9.
Discriminative stimulus effects of zolpidem in squirrel monkeys: role of GABA(A)/alpha1 receptors.
Psychopharmacology (Berl)
; 165(3): 209-15, 2003 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-12420154
10.
Role of GABAA/benzodiazepine receptors containing alpha 1 and alpha 5 subunits in the discriminative stimulus effects of triazolam in squirrel monkeys.
Psychopharmacology (Berl)
; 161(2): 180-8, 2002 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-11981598
11.
The CRF(1) receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats.
Psychopharmacology (Berl)
; 165(1): 86-92, 2002 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-12474122
12.
Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats.
Eur J Pharmacol
; 737: 47-56, 2014 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24821570
13.
Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.
ACS Med Chem Lett
; 5(7): 760-5, 2014 Jul 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-25050161
14.
Pharmacological and behavioral characterization of the novel CRF1 antagonist BMS-763534.
Neuropharmacology
; 67: 284-93, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23174340
15.
NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the gerbil forced swim test.
Neuropharmacology
; 73: 232-40, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23770339
16.
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
J Med Chem
; 52(9): 3084-92, 2009 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-19361209
17.
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
J Med Chem
; 52(9): 3073-83, 2009 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-19361210
18.
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
J Med Chem
; 52(14): 4161-72, 2009 Jul 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-19552436
19.
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
J Med Chem
; 52(23): 7653-68, 2009 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-19954247
20.
Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.
J Med Chem
; 52(14): 4173-91, 2009 Jul 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-19552437